Drug Profile
Repotrectinib - Turning Point Therapeutics
Alternative Names: Augtyro; BMS-986472; Ropotrectinib; TPX 0005; ZL-2308Latest Information Update: 10 Apr 2024
Price :
$50
*
At a glance
- Originator TP Therapeutics
- Developer Turning Point Therapeutics; ZAI Lab
- Class Antineoplastics; Aza compounds; Fluorobenzenes; Ketones; Macrocyclic compounds; Pyrazoles; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Focal adhesion protein-tyrosine kinase inhibitors; Janus kinase-2 inhibitors; ROS1 protein inhibitors; Src-Family kinase inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Non-small cell lung cancer
- Preregistration Solid tumours
- Phase I/II CNS cancer; Lymphoma
- Preclinical Multiple myeloma
Most Recent Events
- 08 Apr 2024 Bristol Myers Squibb plans a phase I safety and pharmacokinetics study in healthy subjects in USA (PO) in April 2024 (NCT06352528)
- 18 Mar 2024 Bristol Myers Squibb in collaboration with MedSIR plans a phase II REPOSE trial for Non small cell lung cancer in Austria in August 2024 (PO) (NCT06315010)
- 22 Feb 2024 Repotrectinib receives priority review status for Solid tumours (In adolescents, In the elderly, Late-stage disease, Metastatic disease, In adults) in USA